CDMO is commissioning third GMP biologics facility in Fremont.
Bionova Scientific, a biologics contract development and manufacturing organization (CDMO) that was acquired by Asahi Kasei Medical last April, has started the commissioning process for its third Fremont, Calif. location. The company’s primary focus will be toward scaling-up its manufacturing capacity and service capabilities.
Currently, the CDMO’s two Fremont facilities feature a headquarters and good manufacturing practice (GMP) facility, and a nearby dedicated warehouse and storage building respectively. The new plant, deemed the Laurelview site due to its location, will act as a replacement HQ and development center; it will also be home to Bionova Scientific’s administrative functions and biologics development teams. Although an expected completion date for the center itself is yet to be announced, the administrative offices and the labs for cell line development, process development, and analytical services are expected to be moved to the new site the middle of this year.
“We are very excited to begin our strategic expansion with this new facility,” says Darren Head, CEO of Bionova. … “Adding the Laurelview development facility gives all our technical teams the opportunity to grow and deepen their expertise. … Our cell line development, process development, and analytical services teams will each have more capacity and resources for development projects.
Read more about the expansion here.